Illumina's revenue has plateaued near $1.0B to $1.2B per quarter with year-over-year growth swinging between roughly -5% and +10%, while gross margin recovered to 73.5% in Q3 2026 from 64.8% in Q2 2024.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue has hovered between roughly $1.0B and $1.2B with gross margin moving from 64.8% to 73.5% and operating margin oscillating between about 19% and 27%, suggesting gross profit gains have not translated into meaningful operating leverage given SG&A held near $240M to $280M.
Illumina reported Q1 2026 revenue of $1,091 million and net income of $134 million, with higher EPS YoY and raised full-year revenue guidance to $4.52-$4.62 billion.
The company repurchased about 7.15% of its stock, demonstrating management's confidence in the business outlook.
Illumina offers a broad range of sequencing and microarray products for various genomic analysis applications, driving advances in research and diagnostics.
Trailing total returns as of 11/7/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Oct 29, 2026 | $1.62+19.1% vs $1.36 | $1.2B+1.1% vs $1.2B |
Q3 2026 Jul 30, 2026 | $1.31+6.5% vs $1.23 | $1.2B+2.5% vs $1.1B |
Q2 2026 Apr 30, 2026 | $1.15+9.5% vs $1.05 | $1.1B+1.7% vs $1.1B |
Q1 2026 Feb 5, 2026 | $1.35+8.9% vs $1.24 | $1.2B+3.6% vs $1.1B |
Genomics and synthetic biology are transforming healthcare through precision medicine and gene editing, putting ILMN, QURE and TXG in focus as the markets expand.
Illumina raises its 2026 guidance as strong clinical sequencing demand and NovaSeq X adoption fuel growth despite research weakness and pricing pressures.
Although the revenue and EPS for Illumina (ILMN) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Illumina, Inc. (ILMN) Q3 2026 Earnings Call Transcript
Benchmark ILMN against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Illumina, Inc. (ILMN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $213.13 | $32.25B | 36.67 | -0.78% | 19.72% | 31.45% | — | |
| $2.26 | $701.96M | -5.36 | 3.89% | -81.31% | -2618.51% | — | |
| $61.31 | $9.33B | -75.77 | 2.08% | -3.51% | -5.05% | 0.24% | |
| $694.76 | $258.19B | 36.39 | 3.91% | 14.96% | 13.3% | 0.24% | |
| $230.25 | $161.86B | 37.58 | 2.9% | 16.91% | 8.18% | 0.54% | |
| $174.76 | $49.36B | 34.35 | 6.73% | 19.53% | 20.47% | 0.57% |
Illumina, Inc. (ILMN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Illumina, Inc. (ILMN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Oct 29, 2026·SEC
Oct 13, 2026·SEC
Jul 30, 2026·SEC
Get notified when ILMN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Illumina, Inc. (ILMN) stock FAQ — growth, dividends, profitability & financials explained
Illumina, Inc. (ILMN) reported $4.54B in revenue over the trailing twelve months. Revenue was $4.34B in fiscal year 2025. That is 915040% more than the $0.5M of fiscal year 1999.
Illumina, Inc. (ILMN) grew revenue by 5.9% over the trailing twelve months, compared with the twelve months before.
Yes. Illumina, Inc. (ILMN) earned $895.0M in net income over the trailing twelve months (a 19.7% net margin).
Illumina, Inc. (ILMN) had a return on equity (ROE) of 31.5% over the trailing twelve months. That is well above the market's typical 10-15%.
Illumina, Inc. (ILMN) generated $1.06B in free cash flow over the trailing twelve months.
